Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC

[
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
[og_img]
https://www.investing.com/news/press-releases/johnson–johnsons-tar200-monotherapy-achieves-high-diseasefree-survival-of-more-than-80-percent-in-bcgunresponsive-highrisk-papillary-nmibc-93CH-4005885


Investing.com